{
    "info": {
        "nct_id": "NCT05993611",
        "official_title": "A First-in-Human Study to Evaluate the Safety, Feasibility and Tolerability of Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Cell Transplantation (alloHCT)",
        "inclusion_criteria": "* PATIENT (RECIPIENT) INCLUSION CRITERIA:\n* All participants must have the ability to understand and the willingness to sign a written informed consent\n* Participants must agree to allow the use of archival tissue from diagnostic biopsies.\n\n  * If unavailable, exceptions may be granted with study PI approval Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed\n* Age >= 18 years\n* Karnofsky performance status of >= 70%\n* Received allogeneic hematopoietic stem cell transplantation (alloHCT) from matched related or haploidentical donor as part of treatment of hematologic disorders Note: The donor needs to consent for leukapheresis\n* Clinical diagnosis of steroid-dependent or refractory, moderate to severe cGVHD\n\n  * Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD per institutional policy despite the use of prednisone for 2 months without complete resolution of signs and symptoms\n* Estimated life expectancy > 90 days\n* Stable dose of corticosteroids for >= 14 days prior to enrollment not exceeding 15mg/day of prednisone or equivalent + with up to 7ng/mL/day sirolimus with therapeutic drug monitoring\n* Exposure to at least 1 of the Food and Drug Administration (FDA) approved tyrosine kinase inhibitor (TKI) therapies for cGVHD\n* Naive to anti-CD6 therapy post most recent alloHCT\n* Absolute neutrophil count (ANC) >= 1,000/mm^3 (without myeloid growth factors within 1 week of study entry) (performed within 28 days prior to enrollment)\n* Platelets >= 50,000/mm^3 (performed within 28 days prior to enrollment) NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment\n* Total bilirubin =< 2 mg/dL (exception permitted in patients with Gilbert's syndrome), unless hepatic dysfunction is a manifestation of presumed cGVHD) (performed within 28 days prior to enrollment) NOTE: Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation\n* Aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN) (performed within 28 days prior to enrollment)\n* Alanine aminotransferase (ALT) =< 3.0 x ULN (performed within 28 days prior to enrollment)\n* Creatinine clearance of >= 30 mL/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 28 days prior to enrollment)\n* Seronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo, hepatitis C virus (HCV)*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]) (performed within 28 days prior to enrollment)\n\n  * If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed OR\n  * If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable\n* Subjects must have negative QuantiFERON-tuberculosis (TB) Gold (QFTG) test (performed within 28 days prior to enrollment). Patients with positive QFTG test need clearance from infectious disease (ID) before enrollment\n* Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)\n* Meets other institutional and federal requirements for infectious disease titer requirements Note Infectious disease testing to be performed within 28 days prior to start of protocol therapy\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (performed within 28 days prior to enrollment) Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Cardiac function (12 lead-electrocardiography [ECG]): corrected QT interval (QTc) must be =< 480 msec (performed within 28 days prior to enrollment)\n* Left ventricular ejection fraction > 40% (performed within 28 days prior to enrollment)\n* Oxygen saturation 92% or above at room air or carbon monoxide diffusing capability test (DLCO) of 40% of best predicted (performed within 28 days prior to enrollment) Note: The above criteria only applies to participants who are not experiencing lung GVHD bronchiolitis obliterans syndrome (BOS)\n* Agreement by females and males of childbearing potential* to use an effective method of birth control** or abstinence from sexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.\n\n  * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\n\n    * Effective birth control defined as hormonal and/or barrier contraception)\n* ALLOGENEIC DONOR CRITERIA FOR APHERESIS DONATION:\n* The identified donor must be the original donor whose stem cells were used for the research participant's alloSCT\n* Karnofsky Performance Status (KPS) >= 70\n* Age: >= 18 years\n* The donor is approved and has completed the donor evaluation per institutional guidelines (as indicated in DACT 122 - Administrative Protocol for Allogeneic Hematopoietic Progenitor Cell, Apheresis [HPC(A)] Collections). Additionally, donor will also be screened for the following infectious diseases:\n\n  * Epstein-Barr virus (EBV),\n  * Human herpes virus 6, 7, and 8 (HHV6, HHV7, HHV8)\n  * Parvovirus B19 Note: ID test results for EBV, HHV6, HHV7, HHV8 and Parvovirus B19 are not necessary to proceed with the apheresis procedure but do have to be resulted and negative before participant CAR Treg infusion\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* PATIENT (RECIPIENT) EXCLUSION CRITERIA:\n* Immunosuppressive therapy within 28 days prior to enrollment (exception: corticosteroid)\n* Concurrent other investigational agents, including biologics\n* Vaccines within 28 days prior to enrollment\n* Donor lymphocyte infusion within 100 days of enrollment\n* No known contraindications to steroids or tocilizumab\n* No current active malignancy* (Exception: Basal or squamous cell carcinoma)\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent\n* Active uncontrolled infection requiring systemic antibiotics and/or anti-virals\n* Other autoimmune/inflammatory disorders\n* Clinically significant uncontrolled illness\n* History of vascular disease (e.g., deep vein thrombosis, stroke)\n* Unstable cardiac disease as defined by one of the following:\n\n  * Cardiac events such as myocardial infarction (MI) within the past 6 months\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Uncontrolled atrial fibrillation or hypertension\n* Females only: Pregnant or breastfeeding\n* Inability to comply with protocol therapy and follow up visits\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Estimated life expectancy > 90 days",
                "criterions": [
                    {
                        "exact_snippets": "Estimated life expectancy > 90 days",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "estimated duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Estimated life expectancy > 90 days",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "estimated duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* All participants must have the ability to understand and the willingness to sign a written informed consent",
                "criterions": [
                    {
                        "exact_snippets": "ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Epstein-Barr virus (EBV),",
                "criterions": [
                    {
                        "exact_snippets": "Epstein-Barr virus (EBV)",
                        "criterion": "Epstein-Barr virus (EBV)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Epstein-Barr virus (EBV)",
                        "criterion": "Epstein-Barr virus (EBV)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects must have negative QuantiFERON-tuberculosis (TB) Gold (QFTG) test (performed within 28 days prior to enrollment). Patients with positive QFTG test need clearance from infectious disease (ID) before enrollment",
                "criterions": [
                    {
                        "exact_snippets": "negative QuantiFERON-tuberculosis (TB) Gold (QFTG) test (performed within 28 days prior to enrollment)",
                        "criterion": "QuantiFERON-tuberculosis (TB) Gold (QFTG) test",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "negative QuantiFERON-tuberculosis (TB) Gold (QFTG) test (performed within 28 days prior to enrollment)",
                        "criterion": "QuantiFERON-tuberculosis (TB) Gold (QFTG) test",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with positive QFTG test need clearance from infectious disease (ID) before enrollment",
                        "criterion": "infectious disease (ID) clearance",
                        "requirement": {
                            "requirement_type": "requirement for positive QFTG test",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "negative QuantiFERON-tuberculosis (TB) Gold (QFTG) test (performed within 28 days prior to enrollment)",
                                "criterion": "QuantiFERON-tuberculosis (TB) Gold (QFTG) test",
                                "requirement": {
                                    "requirement_type": "result",
                                    "expected_value": "negative"
                                }
                            },
                            {
                                "exact_snippets": "negative QuantiFERON-tuberculosis (TB) Gold (QFTG) test (performed within 28 days prior to enrollment)",
                                "criterion": "QuantiFERON-tuberculosis (TB) Gold (QFTG) test",
                                "requirement": {
                                    "requirement_type": "timeframe",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days prior to enrollment"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Patients with positive QFTG test need clearance from infectious disease (ID) before enrollment",
                        "criterion": "infectious disease (ID) clearance",
                        "requirement": {
                            "requirement_type": "requirement for positive QFTG test",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count (ANC) >= 1,000/mm^3 (without myeloid growth factors within 1 week of study entry) (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) >= 1,000/mm^3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "without myeloid growth factors within 1 week of study entry",
                        "criterion": "myeloid growth factor use",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "without myeloid growth factors within 1 week of study entry",
                        "criterion": "myeloid growth factor use",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 1 week of study entry"
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "ANC laboratory test timing",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to enrollment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) >= 1,000/mm^3",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "ANC laboratory test timing",
                        "requirement": {
                            "requirement_type": "time window",
                            "expected_value": "within 28 days prior to enrollment"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "without myeloid growth factors within 1 week of study entry",
                                "criterion": "myeloid growth factor use",
                                "requirement": {
                                    "requirement_type": "absence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "without myeloid growth factors within 1 week of study entry",
                                "criterion": "myeloid growth factor use",
                                "requirement": {
                                    "requirement_type": "time window",
                                    "expected_value": "within 1 week of study entry"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Seronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo, hepatitis C virus (HCV)*, active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR]) (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "Seronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "serostatus",
                            "expected_value": "seronegative"
                        }
                    },
                    {
                        "exact_snippets": "Seronegative for ... hepatitis C virus (HCV)",
                        "criterion": "hepatitis C virus infection",
                        "requirement": {
                            "requirement_type": "serostatus",
                            "expected_value": "seronegative"
                        }
                    },
                    {
                        "exact_snippets": "active hepatitis B virus (HBV) (surface antigen negative)",
                        "criterion": "hepatitis B virus infection",
                        "requirement": {
                            "requirement_type": "surface antigen status",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "Seronegative for ... syphilis (rapid plasma reagin [RPR])",
                        "criterion": "syphilis infection",
                        "requirement": {
                            "requirement_type": "serostatus",
                            "expected_value": "seronegative"
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "infectious disease serology testing timing",
                        "requirement": {
                            "requirement_type": "time before enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Seronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo",
                                "criterion": "HIV infection",
                                "requirement": {
                                    "requirement_type": "serostatus",
                                    "expected_value": "seronegative"
                                }
                            },
                            {
                                "exact_snippets": "Seronegative for ... hepatitis C virus (HCV)",
                                "criterion": "hepatitis C virus infection",
                                "requirement": {
                                    "requirement_type": "serostatus",
                                    "expected_value": "seronegative"
                                }
                            },
                            {
                                "exact_snippets": "active hepatitis B virus (HBV) (surface antigen negative)",
                                "criterion": "hepatitis B virus infection",
                                "requirement": {
                                    "requirement_type": "surface antigen status",
                                    "expected_value": "negative"
                                }
                            },
                            {
                                "exact_snippets": "Seronegative for ... syphilis (rapid plasma reagin [RPR])",
                                "criterion": "syphilis infection",
                                "requirement": {
                                    "requirement_type": "serostatus",
                                    "expected_value": "seronegative"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "infectious disease serology testing timing",
                        "requirement": {
                            "requirement_type": "time before enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)",
                "criterions": [
                    {
                        "exact_snippets": "not being surgically sterilized (men and women)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "have not been free from menses for > 1 year (women only)",
                        "criterion": "menstrual status",
                        "requirement": {
                            "requirement_type": "free from menses duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "have not been free from menses for > 1 year (women only)",
                        "criterion": "menstrual status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "not being surgically sterilized (men and women)",
                        "criterion": "surgical sterilization status",
                        "requirement": {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "have not been free from menses for > 1 year (women only)",
                                "criterion": "menstrual status",
                                "requirement": {
                                    "requirement_type": "free from menses duration",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 1,
                                        "unit": "year"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "have not been free from menses for > 1 year (women only)",
                                "criterion": "menstrual status",
                                "requirement": {
                                    "requirement_type": "sex",
                                    "expected_value": "female"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Oxygen saturation 92% or above at room air or carbon monoxide diffusing capability test (DLCO) of 40% of best predicted (performed within 28 days prior to enrollment) Note: The above criteria only applies to participants who are not experiencing lung GVHD bronchiolitis obliterans syndrome (BOS)",
                "criterions": [
                    {
                        "exact_snippets": "Oxygen saturation 92% or above at room air",
                        "criterion": "oxygen saturation",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Oxygen saturation 92% or above at room air",
                        "criterion": "oxygen saturation",
                        "requirement": {
                            "requirement_type": "condition",
                            "expected_value": "at room air"
                        }
                    },
                    {
                        "exact_snippets": "carbon monoxide diffusing capability test (DLCO) of 40% of best predicted",
                        "criterion": "carbon monoxide diffusing capability (DLCO)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 40,
                                "unit": "% of best predicted"
                            }
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "DLCO test timing",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "within 28 days prior to enrollment"
                        }
                    },
                    {
                        "exact_snippets": "The above criteria only applies to participants who are not experiencing lung GVHD bronchiolitis obliterans syndrome (BOS)",
                        "criterion": "lung GVHD bronchiolitis obliterans syndrome (BOS)",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "The above criteria only applies to participants who are not experiencing lung GVHD bronchiolitis obliterans syndrome (BOS)",
                    "criterion": "lung GVHD bronchiolitis obliterans syndrome (BOS)",
                    "requirement": {
                        "requirement_type": "absence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "or_criteria": [
                        {
                            "and_criteria": [
                                {
                                    "exact_snippets": "Oxygen saturation 92% or above at room air",
                                    "criterion": "oxygen saturation",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 92,
                                            "unit": "%"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "Oxygen saturation 92% or above at room air",
                                    "criterion": "oxygen saturation",
                                    "requirement": {
                                        "requirement_type": "condition",
                                        "expected_value": "at room air"
                                    }
                                }
                            ]
                        },
                        {
                            "and_criteria": [
                                {
                                    "exact_snippets": "carbon monoxide diffusing capability test (DLCO) of 40% of best predicted",
                                    "criterion": "carbon monoxide diffusing capability (DLCO)",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 40,
                                            "unit": "% of best predicted"
                                        }
                                    }
                                },
                                {
                                    "exact_snippets": "performed within 28 days prior to enrollment",
                                    "criterion": "DLCO test timing",
                                    "requirement": {
                                        "requirement_type": "recency",
                                        "expected_value": "within 28 days prior to enrollment"
                                    }
                                }
                            ]
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Left ventricular ejection fraction > 40% (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "Left ventricular ejection fraction > 40%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular ejection fraction > 40%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "assessment recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Left ventricular ejection fraction > 40%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 40,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular ejection fraction > 40%",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "assessment recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)",
                        "criterion": "coronavirus disease 2019 (COVID-19) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)",
                        "criterion": "coronavirus disease 2019 (COVID-19) infection",
                        "requirement": {
                            "requirement_type": "test_timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 72,
                                        "unit": "hours"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)",
                        "criterion": "coronavirus disease 2019 (COVID-19) infection",
                        "requirement": {
                            "requirement_type": "test_performance_window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)",
                        "criterion": "coronavirus disease 2019 (COVID-19) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)",
                        "criterion": "coronavirus disease 2019 (COVID-19) infection",
                        "requirement": {
                            "requirement_type": "test_timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 72,
                                        "unit": "hours"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Negative for coronavirus disease 2019 (COVID-19) within 72 hours of day 0 of protocol therapy (performed within 28 days prior to enrollment)",
                        "criterion": "coronavirus disease 2019 (COVID-19) infection",
                        "requirement": {
                            "requirement_type": "test_performance_window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* The identified donor must be the original donor whose stem cells were used for the research participant's alloSCT",
                "criterions": [
                    {
                        "exact_snippets": "The identified donor must be the original donor whose stem cells were used for the research participant's alloSCT",
                        "criterion": "identified donor",
                        "requirement": {
                            "requirement_type": "identity",
                            "expected_value": "original donor whose stem cells were used for the research participant's alloSCT"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "The identified donor must be the original donor whose stem cells were used for the research participant's alloSCT",
                        "criterion": "identified donor",
                        "requirement": {
                            "requirement_type": "identity",
                            "expected_value": "original donor whose stem cells were used for the research participant's alloSCT"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Age: >= 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age: >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age: >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed OR",
                "criterions": [
                    {
                        "exact_snippets": "If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                        "criterion": "hepatitis C virus infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                        "criterion": "hepatitis C virus infection",
                        "requirement": {
                            "requirement_type": "RNA quantitation performed",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                    "criterion": "hepatitis C virus infection",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "exact_snippets": "If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",
                    "criterion": "hepatitis C virus infection",
                    "requirement": {
                        "requirement_type": "RNA quantitation performed",
                        "expected_value": true
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD per institutional policy despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                "criterions": [
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "refractoriness to steroids",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "prednisone treatment duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "response to prednisone",
                            "expected_value": "no complete resolution of signs and symptoms"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "refractoriness to steroids",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "prednisone treatment duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Steroid refractory cGVHD defined as having persistent signs and symptoms of cGVHD ... despite the use of prednisone for 2 months without complete resolution of signs and symptoms",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "response to prednisone",
                            "expected_value": "no complete resolution of signs and symptoms"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* The donor is approved and has completed the donor evaluation per institutional guidelines (as indicated in DACT 122 - Administrative Protocol for Allogeneic Hematopoietic Progenitor Cell, Apheresis [HPC(A)] Collections). Additionally, donor will also be screened for the following infectious diseases:",
                "criterions": [
                    {
                        "exact_snippets": "The donor is approved",
                        "criterion": "donor approval status",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "has completed the donor evaluation per institutional guidelines",
                        "criterion": "donor evaluation completion",
                        "requirement": {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "donor will also be screened for the following infectious diseases",
                        "criterion": "infectious disease screening",
                        "requirement": {
                            "requirement_type": "screening",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "The donor is approved",
                        "criterion": "donor approval status",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "has completed the donor evaluation per institutional guidelines",
                        "criterion": "donor evaluation completion",
                        "requirement": {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "donor will also be screened for the following infectious diseases",
                        "criterion": "infectious disease screening",
                        "requirement": {
                            "requirement_type": "screening",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Cardiac function (12 lead-electrocardiography [ECG]): corrected QT interval (QTc) must be =< 480 msec (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "corrected QT interval (QTc) must be =< 480 msec",
                        "criterion": "corrected QT interval (QTc)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "corrected QT interval (QTc) must be =< 480 msec",
                        "criterion": "corrected QT interval (QTc)",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 480,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Meets other institutional and federal requirements for infectious disease titer requirements Note Infectious disease testing to be performed within 28 days prior to start of protocol therapy",
                "criterions": [
                    {
                        "exact_snippets": "Meets other institutional and federal requirements for infectious disease titer requirements",
                        "criterion": "infectious disease titer",
                        "requirement": {
                            "requirement_type": "compliance",
                            "expected_value": "meets institutional and federal requirements"
                        }
                    },
                    {
                        "exact_snippets": "Infectious disease testing to be performed within 28 days prior to start of protocol therapy",
                        "criterion": "infectious disease testing",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to start of protocol therapy"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Meets other institutional and federal requirements for infectious disease titer requirements",
                        "criterion": "infectious disease titer",
                        "requirement": {
                            "requirement_type": "compliance",
                            "expected_value": "meets institutional and federal requirements"
                        }
                    },
                    {
                        "exact_snippets": "Infectious disease testing to be performed within 28 days prior to start of protocol therapy",
                        "criterion": "infectious disease testing",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to start of protocol therapy"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN) (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x upper limit of normal (ULN)"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "AST test timing",
                        "requirement": {
                            "requirement_type": "time from test to enrollment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST) =< 3.0 x upper limit of normal (ULN)",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 3.0,
                                        "unit": "x upper limit of normal (ULN)"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "AST test timing",
                        "requirement": {
                            "requirement_type": "time from test to enrollment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Human herpes virus 6, 7, and 8 (HHV6, HHV7, HHV8)",
                "criterions": [
                    {
                        "exact_snippets": "Human herpes virus 6",
                        "criterion": "Human herpes virus 6 (HHV6) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Human herpes virus 7",
                        "criterion": "Human herpes virus 7 (HHV7) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Human herpes virus 8",
                        "criterion": "Human herpes virus 8 (HHV8) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Human herpes virus 6",
                        "criterion": "Human herpes virus 6 (HHV6) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Human herpes virus 7",
                        "criterion": "Human herpes virus 7 (HHV7) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Human herpes virus 8",
                        "criterion": "Human herpes virus 8 (HHV8) infection",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Agreement by females and males of childbearing potential* to use an effective method of birth control** or abstinence from sexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential* to use an effective method of birth control** or abstinence from sexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.",
                        "criterion": "contraception or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "agreement to use effective birth control or abstain from sexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential* to use an effective method of birth control** or abstinence from sexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.",
                        "criterion": "contraception or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential* to use an effective method of birth control** or abstinence from sexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.",
                        "criterion": "contraception or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "agreement to use effective birth control or abstain from sexual activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Agreement by females and males of childbearing potential* to use an effective method of birth control** or abstinence from sexual activity for the course of the study through at least 6 months after the last dose of protocol therapy.",
                        "criterion": "contraception or abstinence during and after study",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Parvovirus B19 Note: ID test results for EBV, HHV6, HHV7, HHV8 and Parvovirus B19 are not necessary to proceed with the apheresis procedure but do have to be resulted and negative before participant CAR Treg infusion",
                "criterions": [
                    {
                        "exact_snippets": "ID test results for EBV ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Epstein-Barr Virus (EBV) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for HHV6 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Human Herpesvirus 6 (HHV6) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for HHV7 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Human Herpesvirus 7 (HHV7) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for HHV8 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Human Herpesvirus 8 (HHV8) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for Parvovirus B19 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Parvovirus B19 infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ID test results for EBV ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Epstein-Barr Virus (EBV) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for HHV6 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Human Herpesvirus 6 (HHV6) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for HHV7 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Human Herpesvirus 7 (HHV7) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for HHV8 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Human Herpesvirus 8 (HHV8) infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "ID test results for Parvovirus B19 ... do have to be resulted and negative before participant CAR Treg infusion",
                        "criterion": "Parvovirus B19 infection",
                        "requirement": {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Alanine aminotransferase (ALT) =< 3.0 x ULN (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) =< 3.0 x ULN",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "ALT test timing",
                        "requirement": {
                            "requirement_type": "time before enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Alanine aminotransferase (ALT) =< 3.0 x ULN",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "performed within 28 days prior to enrollment",
                        "criterion": "ALT test timing",
                        "requirement": {
                            "requirement_type": "time before enrollment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelets >= 50,000/mm^3 (performed within 28 days prior to enrollment) NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment",
                "criterions": [
                    {
                        "exact_snippets": "Platelets >= 50,000/mm^3 (performed within 28 days prior to enrollment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "mm^3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets >= 50,000/mm^3 (performed within 28 days prior to enrollment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": "within 28 days prior to enrollment"
                        }
                    },
                    {
                        "exact_snippets": "Platelet transfusions are not permitted within 14 days of platelet assessment",
                        "criterion": "platelet transfusion",
                        "requirement": {
                            "requirement_type": "permitted_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "within 14 days of platelet assessment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets >= 50,000/mm^3 (performed within 28 days prior to enrollment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "mm^3"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets >= 50,000/mm^3 (performed within 28 days prior to enrollment)",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": "within 28 days prior to enrollment"
                        }
                    },
                    {
                        "exact_snippets": "Platelet transfusions are not permitted within 14 days of platelet assessment",
                        "criterion": "platelet transfusion",
                        "requirement": {
                            "requirement_type": "permitted_within_timeframe",
                            "expected_value": {
                                "operator": "=",
                                "value": 0,
                                "unit": "within 14 days of platelet assessment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Participants must agree to allow the use of archival tissue from diagnostic biopsies.",
                "criterions": [
                    {
                        "exact_snippets": "agree to allow the use of archival tissue from diagnostic biopsies",
                        "criterion": "archival tissue from diagnostic biopsies",
                        "requirement": {
                            "requirement_type": "permission for use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "agree to allow the use of archival tissue from diagnostic biopsies",
                        "criterion": "archival tissue from diagnostic biopsies",
                        "requirement": {
                            "requirement_type": "permission for use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Karnofsky Performance Status (KPS) >= 70",
                "criterions": [
                    {
                        "exact_snippets": "Karnofsky Performance Status (KPS) >= 70",
                        "criterion": "Karnofsky Performance Status (KPS)",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Karnofsky Performance Status (KPS) >= 70",
                        "criterion": "Karnofsky Performance Status (KPS)",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* If unavailable, exceptions may be granted with study PI approval Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed",
                "criterions": [
                    {
                        "exact_snippets": "For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator",
                        "criterion": "English language proficiency",
                        "requirement": {
                            "requirement_type": "proficiency",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "a short form consent may be used with a City of Hope (COH) certified interpreter/translator",
                        "criterion": "availability of COH certified interpreter/translator",
                        "requirement": {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator",
                    "criterion": "English language proficiency",
                    "requirement": {
                        "requirement_type": "proficiency",
                        "expected_value": false
                    }
                },
                "then_criteria": {
                    "exact_snippets": "a short form consent may be used with a City of Hope (COH) certified interpreter/translator",
                    "criterion": "availability of COH certified interpreter/translator",
                    "requirement": {
                        "requirement_type": "availability",
                        "expected_value": true
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* ALLOGENEIC DONOR CRITERIA FOR APHERESIS DONATION:",
                "criterions": [
                    {
                        "exact_snippets": "ALLOGENEIC DONOR CRITERIA FOR APHERESIS DONATION",
                        "criterion": "allogeneic donor eligibility for apheresis donation",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ALLOGENEIC DONOR CRITERIA FOR APHERESIS DONATION",
                        "criterion": "allogeneic donor eligibility for apheresis donation",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Karnofsky performance status of >= 70%",
                "criterions": [
                    {
                        "exact_snippets": "Karnofsky performance status of >= 70%",
                        "criterion": "Karnofsky performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Karnofsky performance status of >= 70%",
                        "criterion": "Karnofsky performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PATIENT (RECIPIENT) INCLUSION CRITERIA:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin =< 2 mg/dL (exception permitted in patients with Gilbert's syndrome), unless hepatic dysfunction is a manifestation of presumed cGVHD) (performed within 28 days prior to enrollment) NOTE: Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin =< 2 mg/dL (exception permitted in patients with Gilbert's syndrome), unless hepatic dysfunction is a manifestation of presumed cGVHD) (performed within 28 days prior to enrollment)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "mg/dL"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total bilirubin =< 2 mg/dL (exception permitted in patients with Gilbert's syndrome), unless hepatic dysfunction is a manifestation of presumed cGVHD) (performed within 28 days prior to enrollment)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "timeframe",
                            "expected_value": "within 28 days prior to enrollment"
                        }
                    },
                    {
                        "exact_snippets": "exception permitted in patients with Gilbert's syndrome",
                        "criterion": "Gilbert's syndrome",
                        "requirement": {
                            "requirement_type": "exception to total bilirubin criterion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unless hepatic dysfunction is a manifestation of presumed cGVHD",
                        "criterion": "hepatic dysfunction due to presumed cGVHD",
                        "requirement": {
                            "requirement_type": "exception to total bilirubin criterion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation",
                        "criterion": "abnormal liver function tests in context of active cGVHD involving other organ systems",
                        "requirement": {
                            "requirement_type": "exception to normal LFTs",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation",
                        "criterion": "abnormal liver function tests in context of active cGVHD involving other organ systems",
                        "requirement": {
                            "requirement_type": "documentation by treating physician",
                            "expected_value": "abnormal LFTs consistent with hepatic cGVHD"
                        }
                    },
                    {
                        "exact_snippets": "Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation",
                        "criterion": "abnormal liver function tests in context of active cGVHD involving other organ systems",
                        "requirement": {
                            "requirement_type": "liver biopsy requirement",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Total bilirubin =< 2 mg/dL (exception permitted in patients with Gilbert's syndrome), unless hepatic dysfunction is a manifestation of presumed cGVHD) (performed within 28 days prior to enrollment)",
                                        "criterion": "total bilirubin",
                                        "requirement": {
                                            "requirement_type": "quantity",
                                            "expected_value": {
                                                "operator": "<=",
                                                "value": 2,
                                                "unit": "mg/dL"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "Total bilirubin =< 2 mg/dL (exception permitted in patients with Gilbert's syndrome), unless hepatic dysfunction is a manifestation of presumed cGVHD) (performed within 28 days prior to enrollment)",
                                        "criterion": "total bilirubin",
                                        "requirement": {
                                            "requirement_type": "timeframe",
                                            "expected_value": "within 28 days prior to enrollment"
                                        }
                                    }
                                ]
                            },
                            {
                                "not_criteria": {
                                    "or_criteria": [
                                        {
                                            "exact_snippets": "exception permitted in patients with Gilbert's syndrome",
                                            "criterion": "Gilbert's syndrome",
                                            "requirement": {
                                                "requirement_type": "exception to total bilirubin criterion",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "unless hepatic dysfunction is a manifestation of presumed cGVHD",
                                            "criterion": "hepatic dysfunction due to presumed cGVHD",
                                            "requirement": {
                                                "requirement_type": "exception to total bilirubin criterion",
                                                "expected_value": true
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "exception permitted in patients with Gilbert's syndrome",
                        "criterion": "Gilbert's syndrome",
                        "requirement": {
                            "requirement_type": "exception to total bilirubin criterion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unless hepatic dysfunction is a manifestation of presumed cGVHD",
                        "criterion": "hepatic dysfunction due to presumed cGVHD",
                        "requirement": {
                            "requirement_type": "exception to total bilirubin criterion",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation",
                                "criterion": "abnormal liver function tests in context of active cGVHD involving other organ systems",
                                "requirement": {
                                    "requirement_type": "exception to normal LFTs",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation",
                                "criterion": "abnormal liver function tests in context of active cGVHD involving other organ systems",
                                "requirement": {
                                    "requirement_type": "documentation by treating physician",
                                    "expected_value": "abnormal LFTs consistent with hepatic cGVHD"
                                }
                            },
                            {
                                "exact_snippets": "Abnormal liver function tests (LFTs) (liver function panel) in the context of active cGVHD involving other organ systems may also be permitted if the treating physician documents the abnormal LFTs as being consistent with hepatic cGVHD and a liver biopsy will not be mandated in this situation",
                                "criterion": "abnormal liver function tests in context of active cGVHD involving other organ systems",
                                "requirement": {
                                    "requirement_type": "liver biopsy requirement",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Stable dose of corticosteroids for >= 14 days prior to enrollment not exceeding 15mg/day of prednisone or equivalent + with up to 7ng/mL/day sirolimus with therapeutic drug monitoring",
                "criterions": [
                    {
                        "exact_snippets": "Stable dose of corticosteroids for >= 14 days prior to enrollment",
                        "criterion": "corticosteroid dose",
                        "requirement": {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Stable dose of corticosteroids for >= 14 days prior to enrollment",
                        "criterion": "corticosteroid dose",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "prior to enrollment"
                        }
                    },
                    {
                        "exact_snippets": "not exceeding 15mg/day of prednisone or equivalent",
                        "criterion": "prednisone (or equivalent) dose",
                        "requirement": {
                            "requirement_type": "maximum dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 15,
                                "unit": "mg/day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "up to 7ng/mL/day sirolimus with therapeutic drug monitoring",
                        "criterion": "sirolimus dose",
                        "requirement": {
                            "requirement_type": "maximum dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "ng/mL/day"
                            }
                        }
                    },
                    {
                        "exact_snippets": "up to 7ng/mL/day sirolimus with therapeutic drug monitoring",
                        "criterion": "sirolimus dose",
                        "requirement": {
                            "requirement_type": "therapeutic drug monitoring",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Stable dose of corticosteroids for >= 14 days prior to enrollment",
                                "criterion": "corticosteroid dose",
                                "requirement": {
                                    "requirement_type": "stability duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Stable dose of corticosteroids for >= 14 days prior to enrollment",
                                "criterion": "corticosteroid dose",
                                "requirement": {
                                    "requirement_type": "timing",
                                    "expected_value": "prior to enrollment"
                                }
                            },
                            {
                                "exact_snippets": "not exceeding 15mg/day of prednisone or equivalent",
                                "criterion": "prednisone (or equivalent) dose",
                                "requirement": {
                                    "requirement_type": "maximum dose",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 15,
                                        "unit": "mg/day"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "up to 7ng/mL/day sirolimus with therapeutic drug monitoring",
                                "criterion": "sirolimus dose",
                                "requirement": {
                                    "requirement_type": "maximum dose",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "ng/mL/day"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "up to 7ng/mL/day sirolimus with therapeutic drug monitoring",
                                "criterion": "sirolimus dose",
                                "requirement": {
                                    "requirement_type": "therapeutic drug monitoring",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Exposure to at least 1 of the Food and Drug Administration (FDA) approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                "criterions": [
                    {
                        "exact_snippets": "Exposure to at least 1 of the Food and Drug Administration (FDA) approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "criterion": "exposure to FDA approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Exposure to at least 1 of the Food and Drug Administration (FDA) approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "criterion": "exposure to FDA approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "requirement": {
                            "requirement_type": "approval_status",
                            "expected_value": "FDA approved"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Exposure to at least 1 of the Food and Drug Administration (FDA) approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "criterion": "exposure to FDA approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "therapy"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Exposure to at least 1 of the Food and Drug Administration (FDA) approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "criterion": "exposure to FDA approved tyrosine kinase inhibitor (TKI) therapies for cGVHD",
                        "requirement": {
                            "requirement_type": "approval_status",
                            "expected_value": "FDA approved"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* If seropositive for HIV, HCV or HBV, nucleic acid quantitation must be performed. Viral load must be undetectable",
                "criterions": [
                    {
                        "exact_snippets": "seropositive for HIV, HCV or HBV",
                        "criterion": "HIV serostatus",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "seropositive for HIV, HCV or HBV",
                        "criterion": "HCV serostatus",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "seropositive for HIV, HCV or HBV",
                        "criterion": "HBV serostatus",
                        "requirement": {
                            "requirement_type": "seropositivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "nucleic acid quantitation must be performed",
                        "criterion": "nucleic acid quantitation",
                        "requirement": {
                            "requirement_type": "performed",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Viral load must be undetectable",
                        "criterion": "viral load",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": "undetectable"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "or_criteria": [
                        {
                            "exact_snippets": "seropositive for HIV, HCV or HBV",
                            "criterion": "HIV serostatus",
                            "requirement": {
                                "requirement_type": "seropositivity",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "seropositive for HIV, HCV or HBV",
                            "criterion": "HCV serostatus",
                            "requirement": {
                                "requirement_type": "seropositivity",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "seropositive for HIV, HCV or HBV",
                            "criterion": "HBV serostatus",
                            "requirement": {
                                "requirement_type": "seropositivity",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "nucleic acid quantitation must be performed",
                            "criterion": "nucleic acid quantitation",
                            "requirement": {
                                "requirement_type": "performed",
                                "expected_value": true
                            }
                        },
                        {
                            "exact_snippets": "Viral load must be undetectable",
                            "criterion": "viral load",
                            "requirement": {
                                "requirement_type": "detectability",
                                "expected_value": "undetectable"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Age >= 18 years",
                "criterions": [
                    {
                        "exact_snippets": "Age >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age >= 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Naive to anti-CD6 therapy post most recent alloHCT",
                "criterions": [
                    {
                        "exact_snippets": "Naive to anti-CD6 therapy post most recent alloHCT",
                        "criterion": "anti-CD6 therapy",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "post most recent alloHCT",
                        "criterion": "allogeneic hematopoietic cell transplantation (alloHCT)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "post most recent"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Naive to anti-CD6 therapy post most recent alloHCT",
                        "criterion": "anti-CD6 therapy",
                        "requirement": {
                            "requirement_type": "prior exposure",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "post most recent alloHCT",
                        "criterion": "allogeneic hematopoietic cell transplantation (alloHCT)",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": "post most recent"
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Donor lymphocyte infusion within 100 days of enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Donor lymphocyte infusion within 100 days of enrollment",
                        "criterion": "donor lymphocyte infusion",
                        "requirement": {
                            "requirement_type": "time since infusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Donor lymphocyte infusion within 100 days of enrollment",
                        "criterion": "donor lymphocyte infusion",
                        "requirement": {
                            "requirement_type": "time since infusion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 100,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Immunosuppressive therapy within 28 days prior to enrollment (exception: corticosteroid)",
                "criterions": [
                    {
                        "exact_snippets": "Immunosuppressive therapy within 28 days prior to enrollment (exception: corticosteroid)",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "exposure_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Immunosuppressive therapy within 28 days prior to enrollment (exception: corticosteroid)",
                        "criterion": "immunosuppressive therapy",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "corticosteroid"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Immunosuppressive therapy within 28 days prior to enrollment (exception: corticosteroid)",
                                "criterion": "immunosuppressive therapy",
                                "requirement": {
                                    "requirement_type": "exposure_within_timeframe",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 28,
                                        "unit": "days prior to enrollment"
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Immunosuppressive therapy within 28 days prior to enrollment (exception: corticosteroid)",
                                    "criterion": "immunosuppressive therapy",
                                    "requirement": {
                                        "requirement_type": "exception",
                                        "expected_value": "corticosteroid"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Females only: Pregnant or breastfeeding",
                "criterions": [
                    {
                        "exact_snippets": "Females only",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Females only",
                                "criterion": "sex",
                                "requirement": {
                                    "requirement_type": "value",
                                    "expected_value": "female"
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "exact_snippets": "Pregnant",
                                        "criterion": "pregnancy status",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "breastfeeding",
                                        "criterion": "breastfeeding status",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Other autoimmune/inflammatory disorders",
                "criterions": [
                    {
                        "exact_snippets": "Other autoimmune/inflammatory disorders",
                        "criterion": "autoimmune or inflammatory disorders",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Other autoimmune/inflammatory disorders",
                        "criterion": "autoimmune or inflammatory disorders",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* PATIENT (RECIPIENT) EXCLUSION CRITERIA:",
                "criterions": [
                    {
                        "exact_snippets": "PATIENT (RECIPIENT) EXCLUSION CRITERIA",
                        "criterion": "patient exclusion criteria",
                        "requirement": {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "PATIENT (RECIPIENT) EXCLUSION CRITERIA",
                    "criterion": "patient exclusion criteria",
                    "requirement": {
                        "requirement_type": "applicability",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Inability to comply with protocol therapy and follow up visits",
                "criterions": [
                    {
                        "exact_snippets": "Inability to comply with protocol therapy",
                        "criterion": "ability to comply with protocol therapy",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Inability to comply with ... follow up visits",
                        "criterion": "ability to comply with follow up visits",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Inability to comply with protocol therapy",
                            "criterion": "ability to comply with protocol therapy",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "Inability to comply with ... follow up visits",
                            "criterion": "ability to comply with follow up visits",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                "criterions": [
                    {
                        "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                        "criterion": "ability to comply with study procedures",
                        "requirement": {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in the opinion of the investigator",
                        "criterion": "investigator's judgment of participant compliance",
                        "requirement": {
                            "requirement_type": "investigator assessment",
                            "expected_value": "satisfactory"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                        "criterion": "ability to comply with study procedures",
                        "requirement": {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in the opinion of the investigator",
                        "criterion": "investigator's judgment of participant compliance",
                        "requirement": {
                            "requirement_type": "investigator assessment",
                            "expected_value": "satisfactory"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Cardiac events such as myocardial infarction (MI) within the past 6 months",
                "criterions": [
                    {
                        "exact_snippets": "Cardiac events such as myocardial infarction (MI) within the past 6 months",
                        "criterion": "myocardial infarction (MI)",
                        "requirement": {
                            "requirement_type": "occurrence_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cardiac events such as myocardial infarction (MI) within the past 6 months",
                        "criterion": "myocardial infarction (MI)",
                        "requirement": {
                            "requirement_type": "occurrence_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No current active malignancy* (Exception: Basal or squamous cell carcinoma)",
                "criterions": [
                    {
                        "exact_snippets": "No current active malignancy",
                        "criterion": "current active malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "(Exception: Basal or squamous cell carcinoma)",
                        "criterion": "basal or squamous cell carcinoma",
                        "requirement": {
                            "requirement_type": "exception to exclusion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "and_criteria": [
                                {
                                    "not_criteria": {
                                        "exact_snippets": "No current active malignancy",
                                        "criterion": "current active malignancy",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": false
                                        }
                                    }
                                },
                                {
                                    "not_criteria": {
                                        "exact_snippets": "(Exception: Basal or squamous cell carcinoma)",
                                        "criterion": "basal or squamous cell carcinoma",
                                        "requirement": {
                                            "requirement_type": "exception to exclusion",
                                            "expected_value": true
                                        }
                                    }
                                }
                            ]
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Clinically significant uncontrolled illness",
                "criterions": [
                    {
                        "exact_snippets": "Clinically significant uncontrolled illness",
                        "criterion": "clinically significant uncontrolled illness",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Clinically significant uncontrolled illness",
                    "criterion": "clinically significant uncontrolled illness",
                    "requirement": {
                        "requirement_type": "presence",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* NYHA (New York Heart Association) heart failure class III-IV",
                "criterions": [
                    {
                        "exact_snippets": "NYHA (New York Heart Association) heart failure class III-IV",
                        "criterion": "NYHA heart failure class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "NYHA (New York Heart Association) heart failure class III-IV",
                        "criterion": "NYHA heart failure class",
                        "requirement": {
                            "requirement_type": "class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 3,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Vaccines within 28 days prior to enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Vaccines within 28 days prior to enrollment",
                        "criterion": "vaccination",
                        "requirement": {
                            "requirement_type": "time since last vaccination",
                            "expected_value": {
                                "operator": ">=",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Vaccines within 28 days prior to enrollment",
                    "criterion": "vaccination",
                    "requirement": {
                        "requirement_type": "time since last vaccination",
                        "expected_value": {
                            "operator": ">=",
                            "value": 28,
                            "unit": "days"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* History of vascular disease (e.g., deep vein thrombosis, stroke)",
                "criterions": [
                    {
                        "exact_snippets": "History of vascular disease",
                        "criterion": "vascular disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "deep vein thrombosis",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of vascular disease",
                        "criterion": "vascular disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "deep vein thrombosis",
                        "criterion": "deep vein thrombosis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "stroke",
                        "criterion": "stroke",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                "criterions": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent",
                        "criterion": "allergic reactions to compounds of similar chemical or biologic composition to study agent",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concurrent other investigational agents, including biologics",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent other investigational agents, including biologics",
                        "criterion": "concurrent use of other investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "including biologics",
                        "criterion": "concurrent use of biologic investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Concurrent other investigational agents, including biologics",
                        "criterion": "concurrent use of other investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "including biologics",
                        "criterion": "concurrent use of biologic investigational agents",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled atrial fibrillation or hypertension",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled atrial fibrillation",
                        "criterion": "atrial fibrillation",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Uncontrolled atrial fibrillation",
                        "criterion": "atrial fibrillation",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "Uncontrolled ... hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Unstable cardiac disease as defined by one of the following:",
                "criterions": [
                    {
                        "exact_snippets": "Unstable cardiac disease",
                        "criterion": "cardiac disease",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Unstable cardiac disease",
                        "criterion": "cardiac disease",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Creatinine clearance of >= 30 mL/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 28 days prior to enrollment)",
                "criterions": [
                    {
                        "exact_snippets": "Creatinine clearance of >= 30 mL/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 28 days prior to enrollment)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance of >= 30 mL/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 28 days prior to enrollment)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "24-hour urine test",
                                "Cockcroft-Gault formula"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Creatinine clearance of >= 30 mL/min per 24-hour urine test or the Cockcroft-Gault formula (performed within 28 days prior to enrollment)",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 28 days prior to enrollment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Effective birth control defined as hormonal and/or barrier contraception)",
                "criterions": [
                    {
                        "exact_snippets": "Effective birth control defined as hormonal and/or barrier contraception",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "hormonal contraception",
                                "barrier contraception"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Effective birth control defined as hormonal and/or barrier contraception",
                        "criterion": "birth control method",
                        "requirement": {
                            "requirement_type": "effectiveness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Clinical diagnosis of steroid-dependent or refractory, moderate to severe cGVHD",
                "criterions": [
                    {
                        "exact_snippets": "Clinical diagnosis of steroid-dependent or refractory, moderate to severe cGVHD",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinical diagnosis of steroid-dependent or refractory, moderate to severe cGVHD",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "steroid dependence or refractoriness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Clinical diagnosis of steroid-dependent or refractory, moderate to severe cGVHD",
                        "criterion": "chronic graft-versus-host disease (cGVHD)",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": [
                                "moderate",
                                "severe"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (performed within 28 days prior to enrollment) Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential (WOCBP)",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential (WOCBP)",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "reproductive status",
                            "expected_value": "of childbearing potential"
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (performed within 28 days prior to enrollment)",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "test type",
                            "expected_value": [
                                "urine pregnancy test",
                                "serum pregnancy test"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (performed within 28 days prior to enrollment)",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "negative urine or serum pregnancy test (performed within 28 days prior to enrollment)",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "test timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 28,
                                "unit": "days prior to enrollment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* Received allogeneic hematopoietic stem cell transplantation (alloHCT) from matched related or haploidentical donor as part of treatment of hematologic disorders Note: The donor needs to consent for leukapheresis",
                "criterions": [
                    {
                        "exact_snippets": "Received allogeneic hematopoietic stem cell transplantation (alloHCT)",
                        "criterion": "allogeneic hematopoietic stem cell transplantation",
                        "requirement": {
                            "requirement_type": "history of procedure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "from matched related or haploidentical donor",
                        "criterion": "donor type for alloHCT",
                        "requirement": {
                            "requirement_type": "donor relationship",
                            "expected_value": [
                                "matched related",
                                "haploidentical"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "The donor needs to consent for leukapheresis",
                        "criterion": "donor consent for leukapheresis",
                        "requirement": {
                            "requirement_type": "consent for leukapheresis",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Active uncontrolled infection requiring systemic antibiotics and/or anti-virals",
                "criterions": [
                    {
                        "exact_snippets": "Active uncontrolled infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Active uncontrolled infection",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "requiring systemic antibiotics and/or anti-virals",
                        "criterion": "infection treatment",
                        "requirement": {
                            "requirement_type": "treatment_requirement",
                            "expected_value": [
                                "systemic antibiotics",
                                "anti-virals"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "* No known contraindications to steroids or tocilizumab",
                "criterions": [
                    {
                        "exact_snippets": "No known contraindications to steroids",
                        "criterion": "contraindications to steroids",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "No known contraindications to ... tocilizumab",
                        "criterion": "contraindications to tocilizumab",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "No known contraindications to steroids",
                        "criterion": "contraindications to steroids",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "No known contraindications to ... tocilizumab",
                        "criterion": "contraindications to tocilizumab",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}